Back in February, newly-confirmed Secretary of Health and & Human Services (HHS) Robert F. Kennedy Jr. promised to reverse decades of industry capture of the public health agencies. Yet, recent moves ...
Having successfully navigated the Humira patent cliff, AbbVie is poised for continued growth.
Today, the Pharmaceutical Reform Alliance (PRA) released a report explaining how the pharmaceutical industry’s anti-competitive and anti-consumer business practices have led to higher healthcare costs ...
A system that allows drug makers to profit from restricted access will never liberalize on its own—and patients will continue ...
On the FDA’s docket this month are two decisions pushed back from 2025, including one for a rare form of obesity and another for dry eye disease.
ETFs representing global drug companies reached a record high after the U.S. Food and Drug Administration (FDA) announced the appointment of Richard Pazdur, its top cancer drug regulator, as the head ...
Big drug companies' pricing deals with the Trump administration barely came up during their most recent round of quarterly earnings calls, in yet another sign that the agreements were mutually ...
After the weight-loss drug boom, and with generics closing in, Big Pharma are gearing up for the next game-changer.
SOLA Pharmaceuticals, Baton Rouge’s only FDA-approved manufacturer, produces generics, transdermal patches, and affordable specialty drugs nationwide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results